GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » EV-to-EBIT

Myos Rens Technology (Myos Rens Technology) EV-to-EBIT : -3.42 (As of May. 13, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Myos Rens Technology's Enterprise Value is $12.31 Mil. Myos Rens Technology's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-3.60 Mil. Therefore, Myos Rens Technology's EV-to-EBIT for today is -3.42.

The historical rank and industry rank for Myos Rens Technology's EV-to-EBIT or its related term are showing as below:

MYOS's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.91
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Myos Rens Technology's Enterprise Value for the quarter that ended in Sep. 2020 was $200.77 Mil. Myos Rens Technology's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $-3.60 Mil. Myos Rens Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -1.79%.


Myos Rens Technology EV-to-EBIT Historical Data

The historical data trend for Myos Rens Technology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myos Rens Technology EV-to-EBIT Chart

Myos Rens Technology Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.63 -17.14 -25.22 -29.67 -31.90

Myos Rens Technology Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.02 -31.90 -29.36 -33.89 -55.72

Competitive Comparison of Myos Rens Technology's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myos Rens Technology's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's EV-to-EBIT falls into.



Myos Rens Technology EV-to-EBIT Calculation

Myos Rens Technology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=12.314/-3.603
=-3.42

Myos Rens Technology's current Enterprise Value is $12.31 Mil.
Myos Rens Technology's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myos Rens Technology  (NAS:MYOS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Myos Rens Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2020 ) =EBIT / Enterprise Value (Q: Sep. 2020 )
=-3.603/200.770192
=-1.79 %

Myos Rens Technology's Enterprise Value for the quarter that ended in Sep. 2020 was $200.77 Mil.
Myos Rens Technology's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myos Rens Technology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Myos Rens Technology (Myos Rens Technology) Business Description

Traded in Other Exchanges
N/A
Address
45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927
Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.
Executives
Joseph Mannello director, officer: Chief Executive Officer C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel director PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock director C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey director 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne director 4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas director 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin 10 percent owner
John Nosta director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren director, 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc 10 percent owner 150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019

Myos Rens Technology (Myos Rens Technology) Headlines

From GuruFocus